The landscape of toxic intermediates in the metabolic networks of pathogenic fungi reveals targets for antifungal drugs
Jan EwaldiD, Paul Mathias JanseniD, Sascha BrunkeiD, Davina Hiller, Christian H. LutheriD, Humberto González‐DíaziD, Marcus T. DittrichiD, André FleißneriD, Bernhard HubeiD, Stefan SchusteriD, Christoph KaletaiD
Abstract
The burden of fungal infections for humans, animals and plants is widely underestimated and comprises deadly infections as well as great economic costs. Despite that, antifungal drugs are scarce and emergence of resistance in fungal strains contributes to a high mortality. To overcome this shortage, we propose toxic intermediates and their controlling enzymes in metabolic pathways as a resource for new targets and provide a web-service, FunTox-Networks to explore the landscape of toxic intermediates in the metabolic networks of fungal pathogens. The toxicity of metabolites is predicted by a new random forest regression model and is available for over one hundred fungal species. Further, for major fungal pathogens, metabolic networks from the KEGG database were enriched with data of toxicity and regulatory effort for each enzyme to support identification of targets. We determined several toxic intermediates in fungal-specific pathways like amino acid synthesis, nitrogen and sulfur assimilation, and the glyoxylate bypass. For the latter, we show experimentally that growth of the pathogen Candida albicans is inhibited when the detoxifying enzymes Mls1 and Hbr2 are deleted and toxic glyoxylate accumulates in the cell. Thus, toxic pathway intermediates and their controlling enzymes represent an untapped resource of antifungal targets.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species
Jana Nysten, Arne Peetermans, … Patrick Van Dijck·mBioPeer-reviewed·Oct 15, 2024
- Targeting methionine synthase in a fungal pathogen causes a metabolic imbalance that impacts cell energetics, growth and virulence
J. Scott, M. Sueiro-Olivares, … J. Amich·bioRxiv·Jun 4, 2020
- Characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole
J. Corrales, L. Ramos-Alonso, … J. Enserink·bioRxiv·Aug 9, 2023
- A guidance into the fungal metabolomic abyss: Network analysis for revealing relationships between exogenous compounds and their outputs
Muralikrishnan Gopalakrishnan Meena, Matthew J. Lane, … Tomás A. Rush·PNAS NexusPeer-reviewed·Sep 29, 2023
- A screen to identify antifungal antagonists reveals a variety of pharmacotherapies induce echinocandin tolerance in Candida albicans.
Parker Reitler, Christian A. DeJarnette, … Glen E. Palmer·Antimicrobial Agents and ChemotherapyPeer-reviewed·Aug 18, 2025
- Systematic Screening of a Glycolysis-targeting Small-molecule Library Identifies Novel Inhibitors of Fungal Morphogenesis in Candida albicans
Dhrumi Shah, Yogita Martoliya, … Sriram Varahan·bioRxiv·Jul 25, 2026